Nanjing Huanglong Biotechnology Co. Ltd.

The test preparation was Aguratimod tablets (specification: 25 mg) developed by Nanjing Huanglong Biotechnology Co., Ltd., and the reference preparation was Aguratimod tablets (trade name: Edexin®, specification: 25 mg) from Hainan Xiansheng Pharmaceutical Co., Ltd. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Telmisartan hydrochlorothiazide tablets (specification: 80mg/12.5mg) developed by Nanjing Huanglong Biotechnology Co., Ltd. were used as the test preparation, and Telmisartan hydrochlorothiazide tablets (Mekasu ®, specification: 80mg/12.5mg) marketed by Boehringer Ingelheim International GmbH were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent; at the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Riociguat tablets (specification: 2.5 mg) developed by Nanjing Huanglong Biotechnology Co., Ltd. were used as the test preparation, and Riociguat tablets (trade name: Adempas®/Angio®; specification: 2.5 mg) from Bayer AG were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent; at the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.